Serbia, Pakistan and two unnamed countries agreed to end-stage testing of potential Chinese Covid-19 vaccines, the companies said.
China National Biotechnology Corporation (CNBG) today announced that Serbia will test two Covid-19 vaccines developed by the company’s Wuhan and Beijing unit, while Pakistan will test potential vaccines. of the unit in Beijing.
“CNBG’s third phase Covid-19 vaccine trial is expected to include 50,000 people from about 10 countries. The process has already begun in the United Arab Emirates, Bahrain, Peru, Morocco, Argentina and Jordan”, Group vice president Zhang Yuntao said.
Potential Covid-19 vaccine developed by CNBG was displayed at a trade fair in Beijing on September 4. Photo: Reuters.
Zhang added that many countries have expressed interest in ordering a total of 500 million doses of their vaccine. He also said CNBG can produce 300 million doses per year after upgrading production techniques and is working on a plan to increase productivity to one billion doses per year.
Helen Yang, director of global strategy and business development at Chinese biotech company Sinovac, said two more countries agreed to test Phase Three with a potential Covid-19 vaccine called CoronaVac, but refused to disclose his name because the information is still confidential. CoronaVac is being tested in Brazil and Indonesia.
Although a final phase of testing is underway to ensure safety and efficacy, China has licensed the use of potential Covid-19 vaccines from Sinovac and CNBG in emergencies for high-risk groups. as medical staff.
Yang said several tens of thousands of people had injected CoronaVac through the emergency program. Meanwhile, CNBG will also soon start vaccinating Chinese employees working at foreign embassies and consulates, Zhang said.